Africa / Kenya

Kenya's First Biopharma Life Sciences Park to Be Built at Konza Technopolis

Kenya's First Biopharma Life Sciences Park to Be Built at Konza Technopolis
  • Apifa Biotech secured grant funding from Sweden's Swedfund to finance preparatory studies for the proposed Biopharma Life Sciences Park at Konza Technopolis
  • The National Treasury approved the public-private partnership between Apifa Biotech and Technopolis Development Authority in April 2026 to proceed to the development phase
  • A consortium of global firms JLL and IQVIA was selected to conduct the feasibility study for the landmark pharma-ceutical manufacturing project

Search option is now available at TUKO! Feel free to search the content on topics/people you enjoy reading about in the top right corner ;)

Kenya is set to get its first dedicated pharma-ceutical and life sciences manufacturing hub after Apifa Biotech secured grant funding from Swedfund International, Sweden's development finance institution, to finance preparatory studies for a proposed Biopharma Life Sciences Park at Konza Technopolis.

Swedfund funding will support feasibility studies for Apifa Biotech’s planned life sciences park in Konza, helping advance efforts to strengthen pharma-ceutical manufacturing in Kenya.Swedfund funding is expected to support feasibility studies for Apifa Biotech’s planned life sciences park in Konza. Photo: Konza Technopolis.
Source: UGC

The announcement was made on November 12, marking a significant step towards reducing Kenya's dependence on imported medicines and strengthening local healthcare manufacturing capacity.

The project is structured as a public-private partnership between Apifa Biotech and the Technopolis Development Authority, and received National Treasury approval in April 2026 to proceed to the development phase.

A consortium comprising global real estate and investment advisory firm Jones Lang LaSalle (JLL) and healthcare research and analytics company IQVIA has been selected to carry out the feasibility study, bringing expertise in life sciences strategy, infrastructure development and investment planning.

Swedfund backs preparatory work

Swedfund's grant will fund the technical and commercial assessments needed to establish the project's viability and lay the groundwork for attracting long-term private investment.

"This funding commitment we are making today will help to advance the necessary groundwork, strengthen project preparation, and create a clear pathway toward maximizing national development outcomes and attracting long-term private investment to develop Kenya's pharma-ceutical and life sciences sector," said Elsa Ekblom, Health Sector Lead, Project Accelerator at Swedfund.

Technopolis Development Authority Chief Executive Officer John Paul Okwiri said the park would transform Konza into a destination for pharma-ceutical manufacturing and biotechnology innovation.

"The Biopharma Life Sciences Park will position Konza as an emerging centre for life sciences and pharma-ceutical manufacturing, helping Kenya move from importing most of its medicines to producing them locally," Okwiri said.

He added that the project illustrates the value of public-private partnerships in mobilising the financing and technical capabilities needed to deliver large-scale infrastructure.

Ambitions for the EAC region

Apifa Biotech Board Chairman Dr. Gerald Macharia and Chief Executive Officer Dr. Keter were present at the signing ceremony, reaffirming the company's commitment to the project.

"We are excited as Apifa Biotech to witness this important milestone. Our engagement with Konza Technopolis and Swedfund's financial support for the project development phase, together with the global experience of JLL and IQVIA, the consortium awarded to conduct the feasibility study, brings us a significant step closer to realizing our vision of establishing a world-class Biopharma Life Sciences manufacturing hub in Kenya for the EAC region," said Dr. Keter.

The proposed park will be designed, developed and financed by Apifa Biotech, and is intended to create a collaborative environment for pharma-ceutical manufacturers, researchers, investors and technology enterprises.

The initiative aligns with the African Union's target of meeting 60% of Africa's health product needs through local production by 2040, as well as Kenya's own policy goal of sourcing at least half of its essential health products domestically.

With the feasibility study now under way, the JLL-IQVIA findings are expected to shape the project's technical requirements, commercial structure and implementation roadmap.

Share this story WhatsApp Facebook X
Originally published by Tuko
View on Tuko

Comments 0

No comments yet. Start the conversation.

Loading the next story…